Non-viral-mediated gene therapy approaches for bone repair

Orthodontics and Craniofacial Research

Volumn 8, Issue 3, 2005, Pages 183-190

  Winn, Shelley R ^a,b   Chen, J C ^a   Gong, X ^a   Bartholomew, S V ^a   Ozaki, W ^a,b   Shreenivas, S ^c  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Collagen; Gene therapy; Gene activated matrix; Plasmid DNA, Poly (alpha hydroxy) acids; Tissue engineering

Indexed keywords

1,2 DIOLEOYLOXY 3 (TRIMETHYLAMMONIUM)PROPANE; 1,2-DIOLEOYLOXY-3-(TRIMETHYLAMMONIUM)PROPANE; BIOMATERIAL; CHOLESTEROL; COLLAGEN TYPE 1; DNA; FLUORESCENT DYE; FUGENE; GREEN FLUORESCENT PROTEIN; LIPID; LIPOSOME; MONOUNSATURATED FATTY ACID; OXAZOLE DERIVATIVE; PHOTOPROTEIN; POLYESTER; POLYETHYLENEIMINE; POLYETHYLOXAZOLINE; POLYLACTIDE; POLYMER; QUATERNARY AMMONIUM DERIVATIVE;

ANIMAL; ARTICLE; BONE REGENERATION; CELL LINE; CHEMISTRY; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSFECTION; GENETICS; HAMSTER; METHODOLOGY; PLASMID;

ANIMALS; BIOCOMPATIBLE MATERIALS; BONE REGENERATION; CELL LINE; CHOLESTEROL; COLLAGEN TYPE I; CRICETINAE; DNA; FATTY ACIDS, MONOUNSATURATED; FLUORESCENT DYES; GENE EXPRESSION REGULATION; GENE THERAPY; GENETIC VECTORS; GREEN FLUORESCENT PROTEINS; LIPIDS; LIPOSOMES; LUMINESCENT PROTEINS; OXAZOLES; PLASMIDS; POLYESTERS; POLYETHYLENEIMINE; POLYMERS; QUATERNARY AMMONIUM COMPOUNDS; TRANSFECTION;

EID: 24344434238     PISSN: 16016335     EISSN: 16016343     Source Type: Journal    
DOI: 10.1111/j.1601-6343.2005.00332.x     Document Type: Article

References (27)

1. Kortebein MJ, Nelson CL, Sadove AM. Retrospective analysis of 135 secondary alveolar cleft grafts using iliac or calvarial bone. J Oral Maxillofac Surg 1991;49:493-98.
2. Culver KW. Gene Therapy. A Primer for Physicians. Larchmont, NY: Mary Ann Liebert Inc, 1996. pp. 1-198.
3. Winn SR, Hu Y, Sfeir C, Hollinger JO. Gene therapy approaches for modulating bone regeneration. Adv Drug Deliv Rev 2000;42:121-38.
4. Warren SM, Fong KD, Chen CM, Loboa EG, Cowan CM, Lorenz HP, et al. Tools and techniques for craniofacial tissue engineering. Tissue Eng 2003;9:187-200.
5. Wolff JA. Naked DNA transport and expression in mammalian cells. Neuromuscul Disord 1997;7:314-8.
6. Felgner PL. Nonviral strategies for gene therapy. Sci Am 1997;276:102-6.
7. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T, et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996;348:370-5.
8. Mathiowitz E, Jacob JS, Jong YS, Carino GP, Chickering DE, Chaturvedi P, et al. Biologically erodable microspheres as potential oral drug delivery systems. Nature 1997;386:410-14.
9. Davis DD. Biomedical applications of nanotechnology-implications for drug targeting and gene therapy. Trends Biotechnol 1997;15:217-24.
10. Fang J, Zhu Y-Y, Smiley E, Bonadio J, Rouleau JP, Goldstein SA, et al. Stimulation of new bone formation by direct transfer of osteogenic plasmid genes. Proc Natl Acad Sci USA 1996;93: 5753-8.
11. Bonadio J, Smiley E, Patil P, Goldstein S. Localized, direct plasmid gene therapy in vivo: Prolonged therapy results in reproducible tissue regeneration. Nat Med 1999;5:753-9.
12. Giannobile WV. Periodontal tissue engineering by growth factors. Bone 1996;19:23-37.
13. Farhood H, Gao X, Son K, Yang YY, Lazo JS, Huang L, et al. Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann NY Acad Sci 1994;716:23-34.
14. Sato Y, Roman M, Tighe H, Lee D, Corr M, Nguyen MD, et al. Immunostimulatory DNA sequences necessary for effective intradermal gene immunization. Science 1996;273:352-4.
15. Kim DO, Uetsuki T, Kaziro Y, Yamaguchi N, Sugano S. Use of the human elongation factor 1 alpha promoter as a versatile and efficient expression system. Gene 1990;91:217- 26.
16. Hu Y, Grainger DW, Winn SR, Hollinger JO. Fabrication of poly (L-lactic acid) foam scaffolds using multiple solvent systems. J Biomed Mater Res 2002;59:563-72.
17. Lieberman JR, Le LQ, Wu L, Finerman GA, Berk A, Witte ON, et al. Regional gene therapy with a BMP-2 producing murine stromal cell line induces heterotopic and orthotopic bone formation in rodents. J Orthop Res 1998;16:330-9.
18. Lieberman JR, Daluiski A, Stevenson S, Wu L, McAllister P, Lee Y, et al. The effect of regional gene therapy with bone morphogenetic protein-2-producing bone-marrow cells on the repair of segmental femoral defects in rats. J Bone Joint Surg 1999;81- A:905-17.
19. Bonadio J, Goldstein SA, Levy RJ. Gene therapy for tissue repair and regneration. Adv Drug Deliv Rev 1998;33:53-69.
20. Shea LD, Smiley E, Bonadio J, Mooney DJ. Controlled DNA delivery from three-dimensional polymer matrices for tissue engineering. Nat Biotech 1999;17:551-4.
21. Ozaki W, Hung C-C, Gong X, Sasaki A, Hollinger JD, Hu Y, et al. Bone regeneration of rat calvarial critical-sized defects with an engineered composite releasing rhBMP-4 plasmid DNA. Plas Reconstr Surg, in press.
22. Lew D, Parker SE, Latimer T, Abai AM, Kuwahara-Rundell A, Doh SC, et al. Cancer gene therapy using plasmid DNA: Pharmacokinetic study of DNA following injection in mice. Hum Gene Ther 1995;6:533-64.
23. Horn NA, Meek JA, Budhazi G, Marquet M. Cancer gene therapy using plasmid DNA: Purification of DNA for human clinical trials. Hum Gene Ther 1995;6:565-73.
24. Parker SE, Vahlsing HL, Serfilippi LM, Franklin CL, Doh SG, Gromkowski SH, et al. Cancer gene therapy using plasmid DNA: Safety evaluation in rodents and non-human primates. Hum Gene Ther 1995;6:575-90.
25. Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV. CpG oligodeoxynucleosides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med 1997;186:1623-31.
26. Weiner GJ, Liu HM, Wooldridge JE, Dahle CE, Krieg AM. Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. Proc Natl Acad Sci USA 1997;94:10833-7.
27. http://www.clinicaltrials.gov/ct/show/NCT00065663?order = 5.